CSTL
CASTLE BIOSCIENCES INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$32.17
+0.64%Year over year
Reported trailing growth
- Revenue
- +3.2%
- EBITDA
- —
- EBIT
- -39.3%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- -31.8%
Forward estimates
Based on analyst estimates
- Revenue
- +11.8%
- EBITDA
- —
- EPS
- -77.3%
Three-year CAGR
- Revenue
- +35.9%
- EBITDA
- -70.3%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -22.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026